Company Overview and News

 
Ganga activist Sant Gopaldas rushed back to AIIMS

4h freepressjournal.in
Rishikesh: Clean Ganga activist Sant Gopaldas, who has been fasting for the conservation of the river since June 24, was admitted to AIIMS for a second time in the last one week on Wednesday. Thirty six-year-old Gopaldas was brought to the institute from Matrisadan, Haridwar in the evening and admitted to the trauma ward, AIIMS PRO Harish Thapaliyal said.
YESBANK 532648 YYBKY

5
Sensex jumps 267 points tracking global cues, strong earnings

4h freepressjournal.in
Mumbai: The equity benchmark Sensex rallied for the fourth straight session Wednesday, and jumped 267 points, on encouraging second quarter earnings by tech major Infosys and positive global cues. The 30- share Sensex soared 267.26 points, or 0.76 per cent, to 35,429.74. It had rallied 1,161 points in the previous three sessions.
BAJAJ-AUTO 500325 RELIANCE 532977 BHRQY 533278 532215 532187 AXISBANK RIGD HDFCBANK 500570 BHARTIARTL TATAMOTORS CLNDY RLNIY YESBANK AXB INDUSINDBK IBN 532648 YYBKY VEDL AXBKY 532454 AXBA ICICIBANK HDB 532174 500180 COALINDIA TTM

5
Sensex logs first fall in 4 days, tanks 383 pts on rupee woes

4h freepressjournal.in
Mumbai: The BSE benchmark Sensex snapped its three-day gains, plunging 383 points due to heavy selling mainly in financial and auto stocks as rising crude prices and rupee volatility spooked investors. The flagship index swung nearly 880 points both ways on alternate bouts of buying and selling during the session. The NSE Nifty too fell by 131.70 points to slip below 10,500-mark. Intense selling pressure was witnessed in select counters led by auto, realty and oil&gas stocks.
BAJAJ-AUTO 500325 RELIANCE 532977 BHRQY 533278 532215 535789 500470 532187 AXISBANK RIGD HDFCBANK HEROMOTOCO 500570 BHARTIARTL TATAMOTORS CLNDY RLNIY YESBANK AXB INDUSINDBK 511072 IBN IDKQY 535322 532648 YYBKY VEDL REPCOHOME AXBKY 500182 IBULHSGFIN 532454 AXBA DHFL ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 HRTQY COALINDIA TTM

 
RBI refuses more time to Rana Kapoor, tells Yes Bank to appoint new chief by February 1

4h freepressjournal.in
Mumbai: The Reserve Bank has refused to give an extension to Yes Bank MD and CEO Rana Kapoor and asked the bank to appoint a new chief by February 1, 2019, the private lender said Wednesday. The Yes Bank board had sought at least a three-month extension for Kapoor from the RBI beyond January 31, 2019. “The Reserve Bank of India has reaffirmed that a successor to Shri Rana Kapoor, MD & CEO, YES Bank should be appointed by February 1, 2019,” the lender said in a stock exchange filing.
YESBANK 532648 YYBKY

 
Indian Institute of Foreign Trade summer placement ends, students grab average Rs 1.48-lakh stipend from Swiggy, Microsoft, others

4h financialexpress
The Indian Institute of Foreign Trade (IIFT) recently concluded its summer placement for the 2018-20 batch with students securing an average stipend of Rs 1.48 lakh per annum. The institute is set up under the Ministry of Commerce and it conducts two rounds of placement each year. According to a statement released by IIT, the summer placements for the batch that will pass out in 2020, witnessed the participation of a large number of companies from different sectors and industries.
YESBANK AXB 500877 APOLLOTYRE 532648 YYBKY AYRQY 532215 AXBKY AXBA 500470 PIDILITIND TTST TATASTEEL TATLY PDLTY AXISBANK 500331

 
RBI refuses more time to Yes Bank CEO Rana Kapoor

4h livemint
The Reserve Bank of India (RBI) has reaffirmed that the successor of Rana Kapoor, Yes Bank managing director and chief executive, should be appointed by 1 February, the bank said in a communication to the BSE. The RBI had earlier said that Kapoor could serve as CEO until 31 January, despite shareholders seeking to extend his term for three more years. But the bank later sought RBI approval to extend Kapoor’s term beyond January as it needs more time to identify and groom a successor.
YESBANK 532648 YYBKY

 
RBI denies more time to Yes Bank CEO Rana Kapoor; asks to appoint new chief by Feb 1

4h financialexpress
The Reserve Bank of India has turned down the request by the board of Yes Bank to extend Rana Kapoor’s tenure as the chief executive officer until September 2019, according to stock market disclosure on Wednesday.
YESBANK 532648 YYBKY

 
With top-level exits across companies, it is good times ahead for executive search firms

2018-10-16 moneycontrol
When former Infosys chief Vishal Sikka stepped down from the CEO post in mid-August 2017, the company appointed executive search firm Egon Zehnder to look for a replacement within a week. In December 2017, Salil Parekh was appointed as the Managing Director and Chief Executive Officer of the IT major.
AXBKY YESBANK AXBA AXB AXISBANK 532648 YYBKY 532215

 
RBI approves 3-year term for Sandeep Bakhshi as ICICI Bank chief

2018-10-16 freepressjournal.in
New Delhi: Adopting a seemingly cautious approach, the Reserve Bank has approved appointment of Sandeep Bakhshi as ICICI Bank’s Managing Director and Chief Executive Officer for three years as against a five-year term sought by the lender. ICICI Bank Tuesday informed the stock exchanges that the Reserve Bank of India (RBI) has cleared Bakhshi’s appointment for three years effective from October 15.
AXBKY YESBANK AXBA ICICIBANK AXB AXISBANK 532174 IBN 532648 YYBKY 532215

 
RBI approves 3-year term for Bakhshi as ICICI Bank chief

2018-10-16 thehindubusinessline
Adopting a seemingly cautious approach, the Reserve Bank has approved appointment of Sandeep Bakhshi as ICICI Bank’s Managing Director and Chief Executive Officer for three years as against a five-year term sought by the lender.
AXBKY YESBANK AXBA ICICIBANK AXB AXISBANK 532174 IBN 532648 YYBKY 532215

4
Sensex reclaims 35K-mark; rises over 200 points on earnings optimism     

2018-10-16 freepressjournal.in
Mumbai: The benchmark BSE Sensex gained almost 219 points to reclaim the 35,000-mark in early trade Tuesday as investors widened their positions ahead of quarterly earnings from some bluechip companies amid positive Asian cues.
BAJAJ-AUTO 532977 BHRQY 500470 532187 HEROMOTOCO 500570 BHARTIARTL TATAMOTORS YESBANK ALNSE INDUSINDBK IBN 532648 YYBKY VEDL 500182 532454 ICICIBANK TTST TATASTEEL TATLY 532174 HRTQY TTM

 
Yes Bank Limited - Allotment of ESOP/ESPS

2018-10-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
YESBANK 532648 YYBKY

 
Yes Bank Limited - Allotment of ESOP/ESPS

2018-10-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
YESBANK 532648 YYBKY

 
Yes Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-10-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
YESBANK 532648 YYBKY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...